<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83681</article-id><article-id pub-id-type="doi">10.7554/eLife.83681</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Erythrocyte invasion-neutralising antibodies prevent <italic>Plasmodium falciparum</italic> RH5 from binding to basigin-containing membrane protein complexes</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-168169"><name><surname>Jamwal</surname><given-names>Abhishek</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294244"><name><surname>Constantin</surname><given-names>Cristina F</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-334427"><name><surname>Hirshi</surname><given-names>Stephan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-294245"><name><surname>Henrich</surname><given-names>Sebastian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-233873"><name><surname>Bildl</surname><given-names>Wolfgang</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-45483"><name><surname>Fakler</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-230963"><name><surname>Draper</surname><given-names>Simon J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9415-1357</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-233874"><name><surname>Schulte</surname><given-names>Uwe</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3557-0591</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-232145"><name><surname>Higgins</surname><given-names>Matthew K</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2870-1955</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf6"/></contrib><aff id="aff1"><institution content-type="dept">Department of Biochemistry</institution>, <institution>University of Oxford</institution>, <addr-line><named-content content-type="city">Oxford</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Institute of Physiology</institution>, <institution>University of Freiburg</institution>, <addr-line><named-content content-type="city">Freiburg</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-65636"><name><surname>Silvie</surname><given-names>Olivier</given-names></name><role>Reviewing editor</role><aff><institution>Sorbonne Université, UPMC Univ Paris 06, INSERM, CNRS</institution>, <country>France</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>matthew.higgins@bioch.ox.ac.uk</email> (MH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>10</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e83681</elocation-id><history><date date-type="received"><day>23</day><month>09</month><year>2022</year></date><date date-type="accepted"><day>04</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Jamwal et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Jamwal et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83681-v1.pdf"/><abstract><p>Basigin is an essential host receptor for invasion of <italic>Plasmodium falciparum</italic> into human erythrocytes, interacting with parasite surface protein PfRH5. PfRH5 is a leading blood-stage malaria vaccine candidate and a target of growth-inhibitory antibodies. Here we show that erythrocyte basigin is exclusively found in one of two macromolecular complexes, bound either to plasma membrane Ca<sup>2+</sup>-ATPase 1/4 (PMCA1/4) or to monocarboxylate transporter 1 (MCT1). PfRH5 binds to each of these complexes with a higher affinity than to isolated basigin ectodomain, making it likely that these are the physiological targets of PfRH5. PMCA-mediated Ca<sup>2+</sup> export is not affected by PfRH5, making it unlikely that this is the mechanism underlying changes in calcium flux at the interface between an erythrocyte and the invading parasite. However, our studies rationalise the function of the most effective growth inhibitory antibodies targeting PfRH5. While these antibodies do not reduce the binding of PfRH5 to monomeric basigin, they do reduce its binding to basigin-PMCA and basigin-MCT complexes. This indicates that the most effective PfRH5-targeting antibodies inhibit growth by sterically blocking the essential interaction of PfRH5 with basigin in its physiological context.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd><italic>P. falciparum</italic></kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010269</institution-id><institution>Wellcome Trust</institution></institution-wrap></funding-source><award-id>20797/Z/20/Z</award-id><principal-award-recipient><name><surname>Jamwal</surname><given-names>Abhishek</given-names></name><name><surname>Hirshi</surname><given-names>Stephan</given-names></name><name><surname>Higgins</surname><given-names>Matthew K</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB 746,TP 20</award-id><principal-award-recipient><name><surname>Fakler</surname><given-names>Bernd</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Sebastian Henrich, is affiliated with Roche Pharma AG. The author has no financial interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Bernd Fakler, is a shareholder of Logopharm GmbH. Logopharm GmbH produces ComplexioLyte 47 used in this study. The company provides ComplexioLyte reagents to academic institutions on a non-profit basis..</p></fn><fn fn-type="conflict" id="conf4"><p>Simon J Draper, is a named inventor on patents related to PfRH5-targeting antibodies.(PCT/GB2105/052205, PCT/GB2017/052608 and PCT/GB2019/052885)..</p></fn><fn fn-type="conflict" id="conf5"><p>Uwe Schulte, is an employee and shareholder of Logopharm GmbH and BF is shareholder of Logopharm GmbH. Logopharm GmbH produces ComplexioLyte 47 used in this study. The company provides ComplexioLyte reagents to academic institutions on a non-profit basis..</p></fn><fn fn-type="conflict" id="conf6"><p>Matthew K Higgins, is a named inventor on patents related to PfRH5-targeting antibodies.(PCT/GB2105/052205, PCT/GB2017/052608 and PCT/GB2019/052885)..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Data within graphs (source data) and uncropped gel and blot images are included with this submission</p></sec><supplementary-material><ext-link xlink:href="elife-83681-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>